BioSpace News Archive

PEP-Therapy, a clinical-stage biotechnology company developing first-in-class peptides as targeted therapies in oncology, and Institut Curie, France’s leading cancer center, announced the dosing of the first patients in a Phase Ib clinical trial evaluating PEP-Therapy’s lead candidate, PEP-010, based on highly encouraging Phase Ia results.

eyeDNA Therapeutics, a newly created subsidiary of Coave Therapeutics announces that updated 12-month and new 24-month follow-up results from its Phase I/II study evaluating the safety and efficacy of HORA-PDE6b, its investigational gene therapy for retinitis pigmentosa caused by bi-allelic mutations in the PDE6B gene will be presented during oral presentations at the Association for Research in Vision and Ophthalmology 2024 meeting in Seattle, WA, USA.

PureTech Health plc announces its results for the year ended December 31, 2023, as well as its cash balance as of the first quarter ended March 31, 2024.

Nucleome Therapeutics today announces the appointment of John Davis, MD, MPH, MS as a Non-Executive Director of the Board, and the foundation of its Scientific Advisory Board (SAB), comprised of world-renowned experts across dark genome genetics and drug discovery.

ImmunityBio, Inc., an immunotherapy company, announced positive overall survival results in the QUILT 3.055 study of 2nd- and 3rd-line NSCLC patients who progressed after checkpoint inhibitor therapy and standard-of-care chemotherapy to be discussed during the upcoming conference call.

Santhera Pharmaceuticals announces the Company’s preliminary unaudited financial results for the year ended December 31, 2023, reports on business progress achieved in 2023 and extending into 2024, and provides updates on its strategic and financing initiatives.

Verona Pharma plc announces that it will report its financial results for the first quarter ended March 31, 2024 on Thursday, May 9, 2024 and host an investment community conference call at 9:00 a.m. EDT / 2:00 p.m. BST to discuss these financial results and provide a corporate update.

Swedish Orphan Biovitrum AB announced its report for the first quarter 2024.

AlzeCure Pharma AlzeCure Pharma AB announced that its interim report for the period January - March 2024 is now available on the company’s website.

Hyundai Bioscience announced on April 25th that its clinical development plan of oral “Niclosamide Metabolic Anticancer Drug” targeting cancer patients with intractable cancer caused by p53 gene mutations.